Serum Proteomic Profiles Suggest Celecoxib-Modulated Targets and Response Predictors

Zhen Xiao, Brian T. Luke, Grant Izmirlian, Asad Umar, Patrick M. Lynch, Robin K.S. Phillips, Sherri Patterson, Thomas P. Conrads, Timothy D. Veenstra, Peter Greenwald, Ernest T. Hawk, Iqbal U. Ali*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

34 Scopus citations


Cyclooxygenase-2 is a valid target for cancer prevention and treatment. This has been shown in preclinical and clinical cancer prevention studies by using a cyclooxygenase-2 inhibitor, celecoxib. When used in a randomized cancer prevention clinical trial on patients with the inherited autosomal dominant condition, familial adenomatous polyposis, celecoxib proved efficacious. However, a remarkable heterogeneity in patients' responses to the chemopreventive effects of celecoxib was observed. Proteomic profiling of sera from these patients identified several markers, the expression of which was specifically modulated after treatment with celecoxib. A decision tree algorithm identified classifiers for response to celecoxib with relatively high sensitivity but moderate to low specificity. In particular, a spectral feature at m/z 16,961.4 was identified as a strong discriminator between response and nonresponse to celecoxib at the highest dose.

Original languageEnglish
Pages (from-to)2904-2909
Number of pages6
JournalCancer Research
Issue number8
StatePublished - 15 Apr 2004
Externally publishedYes


Dive into the research topics of 'Serum Proteomic Profiles Suggest Celecoxib-Modulated Targets and Response Predictors'. Together they form a unique fingerprint.

Cite this